ArticleBlood2004
Identification of an HLA-A*0201-restricted CD8+ T-cell epitope SSp-1 of SARS-CoV spike protein.
Article in Blood, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 91 citations in OpenAlex.
- Study of the Effects of Several SARS-CoV-2 Structural Proteins on Antiviral Immunity.Vaccines · 2023Article
- Functional studies of HLA and its role in SARS-CoV-2: Stimulating T cell response and vaccine development.Life sciences · 2023Review
- Early CD4Scientific reports · 2022Article
- In silico Design and Characterization of Multi-epitopes Vaccine for SARS-CoV2 from Its Spike Protein.International journal of peptide research and therapeutics · 2022Article
- Screening HLA-A-restricted T cell epitopes of SARS-CoV-2 and the induction of CD8Cellular & molecular immunology · 2021Article
- Landscape and selection of vaccine epitopes in SARS-CoV-2.Genome medicine · 2021Article
- The ORF8 protein of SARS-CoV-2 mediates immune evasion through down-regulating MHC-Ι.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Design of an epitope-based peptide vaccine against the SARS-CoV-2: a vaccine-informatics approach.Briefings in bioinformatics · 2021Article
- Leveraging on the genomics and immunopathology of SARS-CoV-2 for vaccines development: prospects and challenges.Human vaccines & immunotherapeutics · 2021Review
- CD8Frontiers in immunology · 2021Article
- The Case for S2: The Potential Benefits of the S2 Subunit of the SARS-CoV-2 Spike Protein as an Immunogen in Fighting the COVID-19 Pandemic.Frontiers in immunology · 2021Article
- SARS-CoV-2 Epitopes Are Recognized by a Public and Diverse Repertoire of Human T Cell Receptors.Immunity · 2020Article
- Older adults lack SARS CoV-2 cross-reactive T lymphocytes directed to human coronaviruses OC43 and NL63.Scientific reports · 2020Article
- Article
- Spiking Pandemic Potential: Structural and Immunological Aspects of SARS-CoV-2.Trends in microbiology · 2020Review
- Article
- Genetic gateways to COVID-19 infection: Implications for risk, severity, and outcomes.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020Review
- Landscape and Selection of Vaccine Epitopes in SARS-CoV-2.bioRxiv : the preprint server for biology · 2020Article
- A Testimony of the Surgent SARS-CoV-2 in the Immunological Panorama of the Human Host.Frontiers in cellular and infection microbiology · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A novel coronavirus, severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV), has been identified as the causal agent of SARS. Spike (S) protein is a major structural glycoprotein of the SARS virus and a potential target for SARS-specific cell-mediated immune responses. A panel of S protein-derived peptides was tested for their binding affinity to HLA-A*0201 molecules. Peptides with high affinity for HLA-A*0201 were then assessed for their capacity to elicit specific immune responses mediated by cytotoxic T lymphocytes (CTLs) both in vivo, in HLA-A2.1/K(b) transgenic mice, and in vitro, from peripheral blood lymphocytes (PBLs) harvested from healthy HLA-A2.1(+) donors. SARS-CoV protein-derived peptide-1 (SSp-1 RLNEVAKNL), induced peptide-specific CTLs both in vivo (transgenic mice) and in vitro (human PBLs), which specifically released interferon-gamma (IFN-gamma) upon stimulation with SSp-1-pulsed autologous dendritic cells (DCs) or T2 cells. SSp-1-specific CTLs also lysed major histocompatibility complex (MHC)-matched tumor cell lines engineered to express S proteins. HLA-A*0201-SSp-1 tetramer staining revealed the presence of significant populations of SSp-1-specific CTLs in SSp-1-induced CD8(+) T cells. We propose that the newly identified epitope SSp-1 will help in the characterization of virus control mechanisms and immunopathology in SARS-CoV infection, and may be relevant to the development of immunotherapeutic approaches for SARS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.